This medicine, approved in 8 days, priced in 21 days, will be on the market as soon as next month

Source: Cypress blue 2018-05-14 nine price HPV vaccine, the negotiation result is out, 1298 yuan / piece! 350 million people benefited ▍ fast, from the approval of new drugs to the price determination, only 21 days, May 10, Hainan public resources trading center issued the notice on the supplement of nine price human papillomavirus vaccine (nine price cervical cancer vaccine) to the shortlist procurement catalogue Inform Chongqing Zhifei biology, the Chinese agent of "moshadong 9-price HPV vaccine", to conduct online price negotiation at 10 a.m on May 11 On May 11, Hainan public resources trading service center announced that the data review and price negotiation of the second type vaccine supplement project in Hainan province had been completed, and the negotiation price of two specifications of nine price human papillomavirus vaccine (Saccharomyces cerevisiae) was 1298 yuan / piece This price is slightly higher than the price of about 1200 yuan / piece in Hong Kong, 1500 yuan / piece in Taiwan, and 1350 yuan / piece estimated by previous experts ▍ Hong Kong suspended the supply of HPV vaccine, which only took 8 days from the application of new drugs to the approval of the mainland It is only a step away from the market! On April 20, MSD's listing application was accepted by CDE; on April 23, it was included in the 28th batch of priority review catalogue by CDE; on April 28, the publicity period just expired, and CDE approved conditional listing; until now, the price has only been determined in 21 days It has created the history of China's new drug market! Mercedes is also awesome On May 10, several medical institutions in Hong Kong announced that they had received a formal notice from MSD of the United States, suspending the supply of nine price HPV vaccine to Hong Kong from now on, with the recovery time to be determined until further notice, the Securities Times reported ▍ as soon as it comes to market in June, the signal for women aged 16-26 is very clear - priority should be given to ensuring the smooth listing of vaccines in the mainland It is not hard to predict that after Hainan, the nine price HPV vaccine will enter the supplement catalogue of all provinces and cities in the country and start negotiations Some experts predict that after two procedures of import declaration and approval, it will be listed in the mainland as soon as June HPV vaccine is the first vaccine in the world to include cancer as an indication The vaccine is suitable for 16 to 26 year old women and is used to prevent cervical cancer, vulvar cancer, vaginal cancer, anal cancer, genital warts, persistent infection, precancerous or atypical lesions caused by HPV Relevant data show that the suitable population for vaccination in China is about 356 million ▍ escorted by the State Council, some new drug approvals have been speeded up to look at the above schedule No wonder the industry marvels that the nine price HPV vaccine is on the rocket! Unprecedented strength, thanks to the support of national policies In the opinions on deepening the reform of the review and approval system and encouraging the innovation of pharmaceutical and medical devices issued by the central office and the state office on October 8, 2017, kaizongmingyi wanted to solve the problem of "there is a gap between the quality of Chinese listed products and the international advanced level" Therefore, a series of suggestions are put forward, including: in order to treat serious life-threatening diseases without effective means of treatment, as well as public health and other urgently needed drugs and medical devices, if the early and mid-term indicators of clinical trials show efficacy and can predict their clinical value, they can be approved for marketing with conditions attached The nine price HPV vaccine of mosadon meets this requirement In addition, the documents of the central office, the state office and the state office give priority to the review and approval of major national science and technology projects and national key R & D plans, as well as new drugs and innovative medical devices that are carried out by the national clinical medical research center and approved by the central management department In the future, there may be more new drugs coming into the market.